SLC5A2 and heart failure: No statistically significant difference was observed in the prescription rates of drugs for heart failure (ACEI/ARB/ARNI, β-blockers, MRAs, SGLT2 inhibitors, and diuretics), oral anticoagulants, and antiplatelets between baseline and follow-up, either in the HIF-PHI group or the oral iron supplementation group.